Emcure Pharmaceuticals Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Emcure Pharmaceuticals Ltd is ₹ 1660 as of 06 May 15:30 . The P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 0 on March 2021 . This represents a CAGR of -100.00% over 2 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 2 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 2484 crore as compare to the Dec '25 revenue of ₹ 2365 crore. This represent the growth of 5.02% The revenue of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 120.64 crore. This represent the decline of -100% The ebitda of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 493.84 crore as compare to the Dec '25 ebitda of ₹ 456.45 crore. This represent the growth of 8.19% The ebitda of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 26.71 crore. This represent the decline of -100% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 243.74 crore over 8 quarters. This represents a CAGR of 26.39% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Emcure Pharmaceuticals Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Emcure Pharmaceuticals Ltd or Syncom Formulations (India) Ltd?

Market cap of Emcure Pharmaceuticals Ltd is 31,471 Cr while Market cap of Syncom Formulations (India) Ltd is 1,350 Cr

What are the key factors driving the stock performance of Emcure Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

The stock performance of Emcure Pharmaceuticals Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Emcure Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

As of May 6, 2026, the Emcure Pharmaceuticals Ltd stock price is INR ₹1660.0. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.37.

How do dividend payouts of Emcure Pharmaceuticals Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Emcure Pharmaceuticals Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.